Tortugas Neuroscience reports positive Phase 2b results for schizophrenia treatment
Obuprazine met the primary endpoint across three dose groups in a 363-patient Phase 2b schizophrenia study, with the strongest dose producing a 16.7-point placebo-adjusted PANSS improvement. Early symptom responses and low discontinuation rates support further development, but longer-term safety and comparative efficacy remain unproven.